AI Enabled Edge Cyagen leverages AI-enabled platforms such as HUGO-GT and AbSeek to accelerate target discovery and pre-clinical validation, presenting a compelling cross-sell opportunity to clients seeking faster, data-driven drug development solutions.

Humanized Models With innovative models like HUGO-GT and HUGO-Ab mice and a large library of 16,000 genetically engineered mouse models via partnerships, Cyagen can address customers seeking more predictive human-relevant preclinical data, enabling upsell into advanced efficacy and safety studies.

Strategic Partnerships Recent multi-year collaborations with institutions like Macau University of Science and Technology and Taconic Biosciences indicate a growth trajectory and open doors for co-development, co-funding, and expanded access to Cyagen’s end-to-end CRO services for potential clients.

Therapeutic Focus Cyagen’s robust CRO services across Neurological Diseases, Oncology, Metabolic Disorders, Ophthalmology, and Autoimmune Diseases align with high-demand therapeutic areas, offering cross-sell potential to sponsors pursuing multi-indication target validation and translational studies.

Global Reach With 18,760+ clients in over 100 countries and a scalable platform combining gene-edited models, AI tools, and full-process CRO services, Cyagen is well-positioned to target mid-market to enterprise biotech and pharma firms seeking global preclinical capacity and rapid study execution.